Petar Bojovic

Associate, Stockholm

Biography

Overview

Petar Bojovic is an associate in our Bank Finance practice in Stockholm and joined White & Case in 2018. He advises banks, private equity funds and corporate borrowers on a variety of domestic and cross-border bank finance transactions, including syndicated and bilateral loans, leveraged acquisition financings and real estate financings.

Prior to joining White & Case, Petar worked at another leading Swedish law firm.

Bars and Courts
Swedish Bar
Education
LLM
University of Gothenburg
Studies in Company Law
University of Glasgow
PG Certificate in International Finance Law
Queen Mary, University of London
Languages
Swedish
English
Serbian

Experience

Representation of Accent Equity 2017 LP in its acquisition of a majority stake in Global Attractions SPI from founders and management, and the related acquisition financing. Global Attractions SPI is a European market leader in equipment for indoor playgrounds and other leisure related activities, and offers turn-key services ranging from concept development and design to production and installation. The group has local presence in fifteen countries and a wide distributor base in twelve countries, together covering five continents.

Representation of IK Investment Partners and Merieux Equity Partners on the acquisition of Mabtech. 

Representation of Adelis Equity's portfolio company Ropo Capital on the acquisition of all shares in Colligent Inkasso, Collector's third-party debt collection subsidiary. Ropo Capital is a leading provider of invoice lifecycle management services in Finland, covering the whole value chain of receivables management. 

Representation of Adelis Equity Partners (Adelis) on its acquisition of Säkra AB. Säkra is one of Sweden's strongest brands in insurance brokerage and financial advisory to private individuals, business owners and the public sector.

Representation of Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) as joint bookrunners on the issuance by Stillfront Group AB (publ), the Swedish game developer of up to SEK 1,000,000,000 senior unsecured floating rate bonds due 2024 governed by Swedish law. The bond was issued for the purposes of refinancing a bridge loan used to finance the acquisition of the US game developer, KIXEYE Inc.

Representation of listed EQT portfolio company Karo Pharma AB on its SEK 3.4 billion (US$360 million) acquisition of Trimb Holding from Avista Capital Partners and other shareholders.

Representation of Summa Equity AB, a private equity firm specializing in investments in companies that help solve global challenges, in its acquisition of Olink Proteomics Holding AB, a Swedish life science company with substantial operations in the US that has developed a unique technology for human biomarker discovery, and the related acquisition financing.

Representation of Nordic private equity firm Accent Equity Partners in connection with the financing of the acquisition of Belid Lighting, one of Scandinavia's leading light fixture supplier, catering to both the home market as well as the professional and industrial segments.

Representation of Carnegie Investment Bank AB (publ), Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) as joint bookrunners on the issuance by Stillfront Group AB (publ) of up to SEK 1,000,000,000 senior unsecured bonds due 2022 governed by Swedish law. Stillfront, an independent creator, publisher and distributor of digital games with a vision to become one of Europe's leading indie game developers and publishers, used the proceeds to refinance existing high yield bonds and for general corporate purposes (including acquisitions).

Representation of BNP Paribas Fortis SA/NV, Coöperatieve Rabobank U.A., trading as Rabobank London, ING Bank N.V., Royal Bank of Canada and Sumitomo Mitsui Banking Corporation Europe Limited, as mandated lead arrangers and bookrunners, on a strategic €400 million syndicated cov-lite financing to Kiwa, a global specialist in testing, inspection and certification (TIC).

Representation of EQT on the public cash offer to the shareholders of Karo Pharma.